Loading...
Amneal Pharmaceuticals, Inc.
AMRX•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$8.09
$-0.08(-0.98%)
Amneal Pharmaceuticals, Inc. (AMRX) Financial Performance & Income Statement Overview
Review Amneal Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
16.73%
↑ 16.73%
Operating Income Growth
21.99%
↑ 21.99%
Net Income Growth
-39.16%
↓ 39.16%
Operating Cash Flow Growth
-14.61%
↓ 14.61%
Operating Margin
12.73%
↑ 12.73%
Gross Margin
36.69%
↑ 36.69%
Net Profit Margin
-0.46%
↓ 0.46%
ROE
-6.90%
↓ 6.90%
ROIC
15.74%
↑ 15.74%
Amneal Pharmaceuticals, Inc. (AMRX) Income Statement & Financial Overview
Review Amneal Pharmaceuticals, Inc.'s (AMRX) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $695.42M | $730.52M | $702.47M | $701.78M |
| Cost of Revenue | $439.53M | $467.64M | $432.91M | $451.83M |
| Gross Profit | $255.89M | $262.87M | $269.56M | $249.95M |
| Gross Profit Ratio | $0.37 | $0.36 | $0.38 | $0.36 |
| R&D Expenses | $40.04M | $56.12M | $61.10M | $37.10M |
| SG&A Expenses | $118.29M | $128.69M | $118.69M | $116.46M |
| Operating Expenses | $158.33M | $187.08M | $178.78M | $167.002M |
| Total Costs & Expenses | $597.86M | $654.73M | $613.66M | $618.84M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | -$56.94M | $61.66M | $65.51M | $65.72M |
| Depreciation & Amortization | $0.00 | $66.13M | $58.96M | $55.57M |
| EBITDA | $100.35M | $112.47M | $146.76M | $151.96M |
| EBITDA Ratio | $0.14 | $0.15 | $0.21 | $0.22 |
| Operating Income | $100.35M | $75.79M | $88.81M | $95.47M |
| Operating Income Ratio | $0.14 | $0.10 | $0.13 | $0.14 |
| Other Income/Expenses (Net) | -$62.86M | -$91.11M | -$73.39M | -$75.06M |
| Income Before Tax | $37.49M | -$15.32M | $15.42M | $20.41M |
| Income Before Tax Ratio | $0.05 | -$0.02 | $0.02 | $0.03 |
| Income Tax Expense | $12.87M | $5.42M | $3.67M | $3.62M |
| Net Income | $24.62M | -$31.08M | -$156000.00 | $5.99M |
| Net Income Ratio | $0.04 | -$0.04 | -$0.00 | $0.009 |
| EPS | $0.04 | -$0.10 | $0.04 | $0.02 |
| Diluted EPS | $0.04 | -$0.10 | $0.04 | $0.02 |
| Weighted Avg Shares Outstanding | $311.05M | $309.85M | $309.65M | $309.12M |
| Weighted Avg Shares Outstanding (Diluted) | $323.96M | $309.85M | $309.65M | $318.96M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan